Seagen

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article may contain excessive or inappropriate references to self-published sources. Please help improve it by removing references to unreliable sources where they are used inappropriately. (July 2020) (Learn how and when to remove this message) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Seagen" – news · newspapers · books · scholar · JSTOR (July 2020) (Learn how and when to remove this message) This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (November 2015) (Learn how and when to remove this message) (Learn how and when to remove this message)

Seagen Inc.

Formerly	Seattle Genetics, Inc. (1997–2020)
Company type	Subsidiary
Traded as	Nasdaq: SGEN
Industry	Biotechnology, pharmaceutical
Founded	1997; 27 years ago (1997)
Headquarters	Bothell, Washington, U.S.
Key people	David R. Epstein (Chief Executive Officer) Roger Dansey M.D. (President, Research and Development) Todd E. Simpson (Chief Financial Officer)
Products	Brentuximab vedotin and other antibody-drug conjugates
Revenue	US$1.96 billion (2022)
Operating income	US$−613 million (2022)
Net income	US$−610 million (2022)
Total assets	US$3.67 billion (2022)
Total equity	US$2.80 billion (2022)
Number of employees	3,256 (2022)
Parent	Pfizer
Website	seagen.com
Footnotes / references [1][2]

Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

The company's flagship product Adcetris (brentuximab vedotin)^[3] is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.

To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program^[4] to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the terms of the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.

In addition to brentuximab vedotin, Seattle Genetics' product pipeline includes enfortumab vedotin, being co-developed with Astellas Pharma, tisotumab vedotin, being co-developed with Genmab, SGN-LIV1A, an ADC targeting LIV-1, and several immuno-oncology agents in phase 1 studies.

In January 2018, the company announced it would acquire Cascadian Therapeutics for $614 million.^[5]

In September 2020, Merck & Co announced it would purchase $1 billion of Seagen's common stock, with both companies co-developing lead treatment: ladiratuzumab vedotin.^[6]

In November 2022, the company announced the appointment of David R. Epstein as Chief Executive Officer and Director.^[7]

Pfizer agreed to acquire Seagen in March 2023.^[8]